BB Biotech’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | $152M | Buy |
1,631,089
+59,700
| +4% | +$5.58M | 3.83% | 9 |
|
|
2018
Q4 | $115M | Buy |
1,571,389
+200,851
| +15% | +$14.6M | 3.67% | 11 |
|
|
2018
Q3 | $120M | Buy |
1,370,538
+230,000
| +20% | +$20.1M | 3.17% | 12 |
|
|
2018
Q2 | $112M | Buy |
1,140,538
+129,200
| +13% | +$12.7M | 3.24% | 13 |
|
|
2018
Q1 | $120M | Sell |
1,011,338
-40,000
| -4% | -$4.76M | 3.33% | 13 |
|
|
2017
Q4 | $134M | Sell |
1,051,338
-60,000
| -5% | -$7.62M | 3.76% | 13 |
|
|
2017
Q3 | $131M | Sell |
1,111,338
-110,000
| -9% | -$12.9M | 3.61% | 11 |
|
|
2017
Q2 | $97.4M | Sell |
1,221,338
-20,000
| -2% | -$1.6M | 2.98% | 12 |
|
|
2017
Q1 | $63.6M | Buy |
1,241,338
+50,000
| +4% | +$2.56M | 2.08% | 14 |
|
|
2016
Q4 | $44.6M | Hold |
1,191,338
| – | – | 1.65% | 14 |
|
|
2016
Q3 | $80.7M | Hold |
1,191,338
| – | – | 2.84% | 13 |
|
|
2016
Q2 | $66.1M | Hold |
1,191,338
| – | – | 2.61% | 13 |
|
|
2016
Q1 | $74.8M | Buy |
1,191,338
+58,839
| +5% | +$3.69M | 2.97% | 11 |
|
|
2015
Q4 | $107M | Hold |
1,132,499
| – | – | 3% | 13 |
|
|
2015
Q3 | $91M | Buy |
1,132,499
+167,000
| +17% | +$13.4M | 2.89% | 13 |
|
|
2015
Q2 | $116M | Buy |
965,499
+130,000
| +16% | +$15.6M | 3.14% | 13 |
|
|
2015
Q1 | $87.2M | Buy |
835,499
+84,211
| +11% | +$8.79M | 2.6% | 16 |
|
|
2014
Q4 | $72.9M | Sell |
751,288
-30,000
| -4% | -$2.91M | 2.36% | 15 |
|
|
2014
Q3 | $61M | Buy |
781,288
+160,000
| +26% | +$12.5M | 2.48% | 13 |
|
|
2014
Q2 | $39.2M | Buy |
621,288
+150,000
| +32% | +$9.48M | 1.86% | 13 |
|
|
2014
Q1 | $31.6M | Hold |
471,288
| – | – | 1.63% | 16 |
|
|
2013
Q4 | $30.3M | Hold |
471,288
| – | – | 1.62% | 14 |
|
|
2013
Q3 | $30.2M | Buy |
471,288
+16,488
| +4% | +$1.06M | 1.64% | 17 |
|
|
2013
Q2 | $14.1M | Buy |
+454,800
| New | +$14.1M | 1.02% | 16 |
|